Use of first-line (1L) nivolumab in combination with low-dose (1 mg/kg) ipilimumab and limited (2 cycles of platinum-doublet) chemotherapy in certain patients with metastatic NSCLC (mNSCLC) for PD-L1 non-expressors and expressors

The Lynx Group: 2021 Ask The Expert MDietrich 2.pdf
Please Click the Issue to Download

Introduction

Use of first-line nivolumab in combination with low-dose (1 mg/kg) ipilimumab and limited (2 cycles of platinum-doublet) chemotherapy in certain patients with metastatic NSCLC for PD-L1 non-expressors and expressors

This resource provides insights from a medical oncologist who specializes in cancer immunotherapy about outcomes from the randomized, phase 3, open-label Checkmate 9LA study, which evaluated OPDIVO + YERVOY plus 2 cycles of platinum-based chemotherapy compared to 4 cycles of platinum-based chemotherapy alone as first-line therapy in patients with stage IV or recurrent NSCLC, no known sensitizing EGFR or ALK aberrations, regardless of histology or PD-L1 expression, and an Eastern Cooperative Oncology Group Performance Status of 0 or 1.

Download to Continue Reading


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: